CN101489554A - 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法 - Google Patents

脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法 Download PDF

Info

Publication number
CN101489554A
CN101489554A CNA2007800273721A CN200780027372A CN101489554A CN 101489554 A CN101489554 A CN 101489554A CN A2007800273721 A CNA2007800273721 A CN A2007800273721A CN 200780027372 A CN200780027372 A CN 200780027372A CN 101489554 A CN101489554 A CN 101489554A
Authority
CN
China
Prior art keywords
substituted
compound
unsubstituted
formula
glucosidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800273721A
Other languages
English (en)
Chinese (zh)
Inventor
T·D·巴特斯
R·A·德维克
G·W·J·弗利特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Priority to CN201510202505.0A priority Critical patent/CN104876855A/zh
Publication of CN101489554A publication Critical patent/CN101489554A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800273721A 2006-05-24 2007-05-22 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法 Pending CN101489554A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510202505.0A CN104876855A (zh) 2006-05-24 2007-05-22 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80277606P 2006-05-24 2006-05-24
US60/802,776 2006-05-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510202505.0A Division CN104876855A (zh) 2006-05-24 2007-05-22 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法

Publications (1)

Publication Number Publication Date
CN101489554A true CN101489554A (zh) 2009-07-22

Family

ID=38779322

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800273721A Pending CN101489554A (zh) 2006-05-24 2007-05-22 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
CN201510202505.0A Pending CN104876855A (zh) 2006-05-24 2007-05-22 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510202505.0A Pending CN104876855A (zh) 2006-05-24 2007-05-22 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法

Country Status (8)

Country Link
US (1) US8975280B2 (enExample)
EP (1) EP2023927B1 (enExample)
JP (2) JP5241709B2 (enExample)
CN (2) CN101489554A (enExample)
CA (1) CA2652958C (enExample)
ES (1) ES2537572T3 (enExample)
HK (1) HK1214261A1 (enExample)
WO (1) WO2007140184A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102595895A (zh) * 2009-09-04 2012-07-18 联合治疗公司 亚氨基糖以及治疗丝状病毒性疾病的方法
CN102625801A (zh) * 2009-09-04 2012-08-01 联合治疗公司 治疗痘病毒感染的方法
CN102625796A (zh) * 2009-09-04 2012-08-01 联合治疗公司 治疗正粘病毒感染的方法
CN107207477A (zh) * 2014-11-05 2017-09-26 伊美根特病毒学公司 用于治疗病毒性疾病的亚氨基糖

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727437A (zh) * 2006-08-02 2012-10-17 牛津大学院长校长专家委员会 病毒感染的脂质体治疗
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
ES2579628T3 (es) 2009-02-23 2016-08-12 Emergent Virology Llc Iminoazúcares y métodos de tratamiento de enfermedades virales
EP2400843B1 (en) * 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
WO2010144759A1 (en) 2009-06-12 2010-12-16 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
WO2014143999A1 (en) * 2013-03-15 2014-09-18 Unither Virology, Llc Antibacterial compounds
CN106102464A (zh) * 2013-05-02 2016-11-09 牛津大学之校长及学者 采用亚氨基糖的糖脂抑制
CA2924026C (en) 2013-09-16 2021-12-28 Emergent Virology Llc Deoxynojirimycin derivatives and methods of their using
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS54106477A (en) 1978-02-03 1979-08-21 Nippon Shinyaku Co Ltd Moranoline derivative
JPS5943949B2 (ja) 1978-09-29 1984-10-25 日本新薬株式会社 モラノリンのｎ−置換誘導体
JPS5943947B2 (ja) * 1978-05-03 1984-10-25 日本新薬株式会社 Ｎ−置換モラノリン誘導体
GB2020278B (en) * 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS5943948B2 (ja) * 1978-07-06 1984-10-25 日本新薬株式会社 置換モラノリン誘導体
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
JPS62155291A (ja) 1985-12-20 1987-07-10 バイエル・アクチエンゲゼルシヤフト ３−アミノ−４，５−ジヒドロキシピペリジン類、それらの製造方法及びそれらの使用
DE3620645A1 (de) * 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US4985445A (en) * 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
JPH0643306B2 (ja) * 1988-02-12 1994-06-08 明治製菓株式会社 癌細胞転移抑制剤
EP0350012A3 (en) * 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
ATE135346T1 (de) * 1988-11-03 1996-03-15 Searle & Co Dideoxy-l-arabinitol derivate als antivirus- verbindungen
US5256788A (en) * 1989-02-13 1993-10-26 Nippon Shinyaku Co. Ltd. Moranoline derivatives and their production and the use of moranoline and its derivatives as a stabilizing agent for enzymes
JPH0675510B2 (ja) 1989-02-13 1994-09-28 日本新薬株式会社 モラノリン誘導体の製法
US5051401A (en) * 1989-04-07 1991-09-24 University Of South Alabama Inhibition of mineral deposition by phosphorylated and related polyanionic peptides
DE4009561A1 (de) 1990-03-24 1991-09-26 Bayer Ag Neue desoxynojirimycinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
EP0536402A4 (en) 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
US5290948A (en) 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
DK0739205T3 (da) 1994-01-13 2000-05-01 Searle & Co Anvendelse af N-alkylderivater af 1,5-didesoxy-1,5-imino-D-glucitol til behandling af hepatitis-B-virusinfektioner
AU1876095A (en) * 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
JP2001522833A (ja) 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
EA004705B1 (ru) * 1998-02-12 2004-06-24 Дж.Д.Серл Энд Ко. Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
WO2001060366A1 (en) 2000-02-14 2001-08-23 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
DE60308378T2 (de) * 2002-03-13 2007-09-20 Unither Pharmaceuticals, Inc. Nicht-Hormonal Verfahren zur männlichen Verhütung
AU2003248960B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
EP3782655A1 (en) * 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102595895A (zh) * 2009-09-04 2012-07-18 联合治疗公司 亚氨基糖以及治疗丝状病毒性疾病的方法
CN102625801A (zh) * 2009-09-04 2012-08-01 联合治疗公司 治疗痘病毒感染的方法
CN102625796A (zh) * 2009-09-04 2012-08-01 联合治疗公司 治疗正粘病毒感染的方法
CN102625796B (zh) * 2009-09-04 2015-03-11 联合治疗公司 治疗正粘病毒感染的方法
CN102625801B (zh) * 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
CN107207477A (zh) * 2014-11-05 2017-09-26 伊美根特病毒学公司 用于治疗病毒性疾病的亚氨基糖
CN107207477B (zh) * 2014-11-05 2022-11-01 伊美根特病毒学公司 用于治疗病毒性疾病的亚氨基糖

Also Published As

Publication number Publication date
CA2652958C (en) 2015-11-17
EP2023927B1 (en) 2015-02-25
EP2023927A2 (en) 2009-02-18
CN104876855A (zh) 2015-09-02
JP2009538336A (ja) 2009-11-05
JP2013129662A (ja) 2013-07-04
US8975280B2 (en) 2015-03-10
JP5241709B2 (ja) 2013-07-17
EP2023927A4 (en) 2013-04-10
CA2652958A1 (en) 2007-12-06
WO2007140184A2 (en) 2007-12-06
ES2537572T3 (es) 2015-06-09
US20070275998A1 (en) 2007-11-29
WO2007140184A3 (en) 2008-11-27
HK1214261A1 (zh) 2016-07-22

Similar Documents

Publication Publication Date Title
HK1214261A1 (zh) 脫氧吉瑞霉素和d-阿拉伯膠素醇類似物及使用方法
US5863903A (en) Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
EP0749423B1 (en) Piperidines and pyrrolidines
Aguilar-Moncayo et al. Bicyclic (galacto) nojirimycin analogues as glycosidase inhibitors: Effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase
López et al. Glycosidase inhibitors: versatile tools in glycobiology
Front et al. N‐Alkyl‐, 1‐C‐Alkyl‐, and 5‐C‐Alkyl‐1, 5‐dideoxy‐1, 5‐imino‐(l)‐ribitols as Galactosidase Inhibitors
Clemente et al. Reductive amination routes in the synthesis of piperidine iminosugars
Schitter et al. Fluorous iminoalditols: a new family of glycosidase inhibitors and pharmacological chaperones
Kooij et al. Glycosidase inhibition by novel guanidinium and urea iminosugar derivatives
US6020344A (en) Enzyme inhibitors and methods of use
WO2006100586A1 (en) Glycosidase-inhibiting iminosugars
Ashmus et al. Rational design of cell active C2-modified DGJ analogues for the inhibition of human α-galactosidase A (GALA)
Blériot et al. Sugar-derived amidines and congeners: structures, glycosidase inhibition and applications
Lundt et al. Fluorescently tagged iminoalditol glycosidase inhibitors as novel biological probes and diagnostics
Markad et al. Polyhydroxylated homoazepanes and 1-deoxy-homonojirimycin analogues: Synthesis and glycosidase inhibition study
US20140296288A1 (en) Imino-sugar c-glycosides, preparation and use thereof
Fröhlich et al. 1-Deoxy-d-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines
Matassini et al. The double reductive amination approach to the synthesis of polyhydroxypiperidines
Fellows et al. Alkaloidal glycosidase inhibitors from plants
Iftikhar et al. An Overview of Debenzylation Methods to Obtain 1-Deoxynojirimycin (DNJ)
Tanabe et al. Syntheses and evaluation as glycosidase inhibitor of 1, 5-dideoxy-1, 5-imino-d-glucitol analogs of salacinol, a potent α-glucosidase inhibitor isolated from Ayurvedic medicine, Salacia reticulata
Martínez-Castro et al. Intramolecular cyclization of alkoxyaminosugars: access to novel glycosidase inhibitor families
Clemente Synthesis of alkylated azasugars and their therapeutic potential against lysosomal storage and neurological disorders: the Gaucher-Parkinson case
Ramesh 1.1 Glycoconjugate processing enzymes
Dumbre Design and synthesis of new azasugars: β-lactam-azasugars hybrids, 1-deoxy-D-galactohomonojirimycin and 1-deoxy-D glucohomonojirimycin as glycosidase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090722